User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.

Primary tabs

Lessire, Sarah [UCL] Douxfils, Jonathan [UNamur] Pochet, Lionel [UNamur] Dincq, Anne-Sophie [UCL] Larock, Anne-Sophie [UCL] Gourdin, Maximilien [UCL] Dogné, Jean-Michel [UNamur] Chatelain, Bernard [UCL] Mullier, François [UCL]

(eng) INTRODUCTION: Estimation of residual rivaroxaban plasma concentrations may be requested before invasive procedures and some patients at high thromboembolic risk will have a bridging therapy with heparins when rivaroxaban is interrupted. OBJECTIVE: The objective of this study was to assess the performance of the STA-Liquid Anti-Xa assay (STA LAX) and the low and normal procedures of the Biophen Direct Factor Xa Inhibitors (DiXaI) assay, in patients with and without bridging with low-molecular-weight heparins (LMWHs). MATERIALS AND METHODS: Seventy-nine blood samples were collected from 77 patients on rivaroxaban at CTROUGH or before an invasive procedure. Rivaroxaban plasma concentrations were estimated using Biophen DiXaI, Biophen DiXaI LOW, and STA LAX and compared to liquid chromatography coupled with mass spectrometry (LC-MS/MS) measurements. Stratifications were performed according to heparin bridging. RESULTS: The Biophen DiXaI LOW and STA LAX showed better correlation with LC-MS/MS measurements than Biophen DiXaI in patients not bridged with LMWH (R: 0.97, 0.96, and 0.91, respectively). However, the performance of Biophen DiXaI LOW and STA LAX decreased when residual LMWH activity was present (R: 0.18 and 0.19 respectively) demonstrating that these tests are not specific to rivaroxaban. CONCLUSION: In patients not bridged with LMWH, we suggest to use the Biophen DiXaI LOW and STA LAX for the estimation of rivaroxaban concentrations <50 ng/mL. These results should be confirmed on a larger cohort of patients. Patients bridged with LMWH have inaccurate estimates of low levels of rivaroxaban and the 3 assays studied should not be used to estimate if it is safe to perform a procedure.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2018
Language Anglais
Journal information "Clinical and Applied Thrombosis / Hemostasis" - Vol. 24, no. 1, p. 129-138 (2018)
Peer reviewed yes
Publisher Sage Publications, Inc. ((United States) Thousand Oaks, CA)
issn 1076-0296
e-issn 1938-2723
Publication status Publié
Affiliations UCL - (MGD) Service d'anesthésiologie
UCL - (MGD) Laboratoire de biologie clinique
UCL - (MGD) Département de pharmacie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - SSS/IREC/MEDA - Pôle de médecine aiguë
Keywords Anticoagulants ; Drug monitoring ; Heparin ; Low-molecular-weight ; Perioperative period ; Rivaroxaban
Links
  1. Douxfils Jonathan, Mani Helen, Minet Valentine, Devalet Bérangère, Chatelain Bernard, Dogné Jean-Michel, Mullier François, Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations, 10.1155/2015/345138
  2. Sherwood M. W., Douketis J. D., Patel M. R., Piccini J. P., Hellkamp A. S., Lokhnygina Y., Spyropoulos A. C., Hankey G. J., Singer D. E., Nessel C. C., Mahaffey K. W., Fox K. A. A., Califf R. M., Becker R. C., , Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), 10.1161/circulationaha.113.005754
  3. Beyer-Westendorf J., Gelbricht V., Forster K., Ebertz F., Kohler C., Werth S., Kuhlisch E., Stange T., Thieme C., Daschkow K., Weiss N., Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry, 10.1093/eurheartj/eht557
  4. Godier Anne, Martin Anne-Céline, Leblanc Isabelle, Mazoyer Elisabeth, Horellou Marie-Hélène, Ibrahim Firas, Flaujac Claire, Golmard Jean-Louis, Rosencher Nadia, Gouin-Thibault Isabelle, Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations, 10.1016/j.thromres.2015.08.006
  5. Kepplinger Jessica, Prakapenia Alexandra, Barlinn Kristian, Siegert Gabriele, Gehrisch Siegmund, Zerna Charlotte, Beyer-Westendorf Jan, Puetz Volker, Reichmann Heinz, Siepmann Timo, Bodechtel Ulf, Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol, 10.1007/s11239-015-1229-z
  6. Cuker Adam, Siegal Deborah M., Crowther Mark A., Garcia David A., Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants, 10.1016/j.jacc.2014.05.065
  7. Samama M. M., Contant G., Spiro T. E., Perzborn E., Guinet C., Gourmelin Y., Le Flem L., Rohde G., Martinoli J. L., , Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls : , 10.1160/th11-06-0391
  8. Douxfils Jonathan, Mullier François, Loosen Claire, Chatelain Christian, Chatelain Bernard, Dogné Jean-Michel, Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature, 10.1016/j.thromres.2012.09.004
  9. Harenberg Job, Krämer Roland, Giese Christina, Marx Svetlana, Weiss Christel, Wehling Martin, Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability, 10.1007/s11239-011-0622-5
  10. Asmis L.M., Alberio L., Angelillo-Scherrer A., Korte W., Mendez A., Reber G., Seifert B., Stricker H., Tsakiris D.A., Wuillemin W.A., Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests, 10.1016/j.thromres.2011.06.031
  11. Douxfils J., Lessire S., Dincq A.-S., Hjemdahl P., Rönquist-Nii Y., Pohanka A., Gourdin M., Chatelain B., Dogné J.-M., Mullier F., Estimation of dabigatran plasma concentrations in the perioperative setting : An ex vivo study using dedicated coagulation assays, 10.1160/th14-09-0808
  12. Mani H., Rohde G., Stratmann G., Hesse C., Herth N., Schwers S., Perzborn E., Lindhoff-Last E., Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin : , 10.1160/th11-12-0832
  13. Königsbrügge Oliver, Quehenberger Peter, Belik Sabine, Weigel Günter, Seger Christoph, Griesmacher Andrea, Pabinger Ingrid, Ay Cihan, Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban, 10.1007/s00277-015-2407-y
  14. Gosselin R., Grant R. P., Adcock D. M., Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays, 10.1111/ijlh.12528
  15. Samama M. M., Amiral J., Guinet C., Perzborn E., Depasse F., An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma : , 10.1160/th10-03-0204
  16. Narouze Samer, Benzon Honorio T., Provenzano David A., Buvanendran Asokumar, De Andres José, Deer Timothy R., Rauck Richard, Huntoon Marc A., Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications : Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain, 10.1097/aap.0000000000000223
  17. Douketis JD, Thromb Haemost, 94, 528 (2005)
  18. O'Donnell Martin J., Kearon Clive, Johnson Judy, Robinson Marlene, Zondag Michelle, Turpie Irene, Turpie Alexander G., Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin, 10.7326/0003-4819-146-3-200702060-00007
  19. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogné J.-M., Mullier F., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban : , 10.1160/th13-04-0274
  20. Rohde G., Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry, 10.1016/j.jchromb.2008.07.015
  21. Pernod Gilles, Albaladejo Pierre, Godier Anne, Samama Charles M., Susen Sophie, Gruel Yves, Blais Normand, Fontana Pierre, Cohen Ariel, Llau Juan V., Rosencher Nadia, Schved Jean-François, de Maistre Emmanuel, Samama Meyer M., Mismetti Patrick, Sié Pierre, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013, 10.1016/j.acvd.2013.04.009
  22. Van Blerk M., Bailleul E., Chatelain B., Demulder A., Devreese K., Douxfils J., Jochmans K., Mullier F., Wijns W., Soumali M. R., Coucke W., Vernelen K., Van de Walle P., Influence of dabigatran and rivaroxaban on routine coagulation assays : A nationwide Belgian survey, 10.1160/th14-02-0161
  23. Cuker A, J Thromb Thrombolysis (2015)
  24. Godier A., Gouin-Thibault I., Rosencher N., Albaladejo P., Gestion des anticoagulants oraux directs pour un acte invasif, 10.1016/j.jmv.2015.02.004
  25. Douketis J. D., Healey J. S., Brueckmann M., Eikelboom J. W., Ezekowitz M. D., Fraessdorf M., Noack H., Oldgren J., Reilly P., Spyropoulos A. C., Wallentin L., Connolly S. J., Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure : Substudy of the RE-LY trial, 10.1160/th14-04-0305
  26. Siegal D., Yudin J., Kaatz S., Douketis J. D., Lim W., Spyropoulos A. C., Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists: Systematic Review and Meta-Analysis of Bleeding and Thromboembolic Rates, 10.1161/circulationaha.112.105221
  27. Steinberg B. A., Peterson E. D., Kim S., Thomas L., Gersh B. J., Fonarow G. C., Kowey P. R., Mahaffey K. W., Sherwood M. W., Chang P., Piccini J. P., Ansell J., , Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), 10.1161/circulationaha.114.011777
  28. Douketis James D., Spyropoulos Alex C., Kaatz Scott, Becker Richard C., Caprini Joseph A., Dunn Andrew S., Garcia David A., Jacobson Alan, Jaffer Amir K., Kong David F., Schulman Sam, Turpie Alexander G.G., Hasselblad Vic, Ortel Thomas L., Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation, 10.1056/nejmoa1501035
  29. Douketis James D., Spyropoulos Alex C., Spencer Frederick A., Mayr Michael, Jaffer Amir K., Eckman Mark H., Dunn Andrew S., Kunz Regina, Perioperative Management of Antithrombotic Therapy, 10.1378/chest.11-2298
  30. Mar Philip L., Familtsev Dmitry, Ezekowitz Michael D., Lakkireddy Dhanunjaya, Gopinathannair Rakesh, Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures, 10.1016/j.ijcard.2015.09.035
  31. Adcock D.M., Gosselin R., Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review, 10.1016/j.thromres.2015.05.001
  32. Gosselin Robert C., Francart Suzanne J., Hawes Emily M., Moll Stephan, Dager William E., Adcock Dorothy M., Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban : Can This Test Be Used to Quantify Drug Level?, 10.1177/1060028015578451
Bibliographic reference Lessire, Sarah ; Douxfils, Jonathan ; Pochet, Lionel ; Dincq, Anne-Sophie ; Larock, Anne-Sophie ; et. al. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.. In: Clinical and Applied Thrombosis / Hemostasis, Vol. 24, no. 1, p. 129-138 (2018)
Permanent URL http://hdl.handle.net/2078.1/177645